 Home > Biochemistry News > Biotechnology News > US$195 million helps AstraZeneca to develop self-amplified RNA vaccines and therapies to reach cooperation

US$195 million helps AstraZeneca to develop self-amplified RNA vaccines and therapies to reach cooperation

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

rna extraction protocol

dna rna converter

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 23, 2021, VaxEquity and AstraZeneca reached a cooperation to advance the company's next-generation self-amplified RNA (saRNA) platform technology and develop transformative RNA vaccines and therapies

VaxEquity's proprietary saRNA includes elements called Innate Inhibitory Proteins (IIPs), which can fine-tune the interferon-based innate immune response to prevent the inhibition of RNA replication, thereby maximizing the expression of the protein encoded by the saRNA

According to the cooperation agreement, VaxEquity can receive a total of up to 195 million U.

Reference materials:

[1] VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.